---
input_text: Longitudinal effect of disease-modifying therapy on left ventricular diastolic
  function in children with sickle cell anemia. Cardiac abnormalities seen in sickle
  cell anemia (SCA) include diastolic dysfunction, which has been shown to be associated
  with high morbidity and early mortality. The effect of disease-modifying therapies
  (DMT) on diastolic dysfunction is poorly understood. We prospectively evaluated
  the effects of hydroxyurea and monthly erythrocyte transfusions on diastolic function
  parameters over 2 years. A total of 204 subjects with HbSS or HbSbeta0-thalassemia
  (mean age 11 +- 3.7 years), unselected for disease severity, had diastolic function
  assessed with surveillance echocardiograms twice, 2 years apart. During this 2-year
  observation period, 112 participants received DMTs (hydroxyurea, n = 72, monthly
  erythrocyte transfusions, n = 40), 34 initiated hydroxyurea, and 58 did not receive
  any DMT. The entire cohort showed an increase in left atrial volume index (LAVi)
  of 3.40 +- 10.86 mL/m2, p = .001 over 2 years. This increase in LAVi was independently
  associated with anemia, high baseline E/e' or LV dilation. Individuals not exposed
  to DMT were younger (mean age 8.8 +- 2.9 years), but at baseline their prevalence
  of abnormal diastolic parameters was similar to that of the DMT-exposed participants
  who were older (mean age 12 +- 3.8 years). Participants on DMTs saw no improvement
  in diastolic function over the study period. In fact, participants on hydroxyurea
  saw a possible worsening in diastolic parameters (14% increase in LAVi and ~5% decrease
  in septal e') but also a ~9% decrease in fetal hemoglobin (HbF) levels. Further
  studies are needed to evaluate if exposure to DMT for a longer duration or achieving
  higher HbF might be beneficial in alleviating diastolic dysfunction.
raw_completion_output: |-
  primary_disease: Sickle cell anemia
  medical_actions: Disease-modifying therapy; Surveillance echocardiograms; Hydroxyurea administration; Monthly erythrocyte transfusions
  symptoms: Diastolic dysfunction; Increase in left atrial volume index (LAVi); Anemia; High baseline E/e'; LV dilation; Worsening in diastolic parameters; Decrease in septal e'; Decrease in fetal hemoglobin (HbF) levels
  chemicals: Hydroxyurea
  action_annotation_relationships: Disease-modifying therapy (with hydroxyurea) TREATS diastolic dysfunction IN Sickle cell anemia; Disease-modifying therapy (with hydroxyurea) TREATS increase in left atrial volume index (LAVi) IN Sickle cell anemia; Disease-modifying therapy (with hydroxyurea) PREVENTS anemia IN Sickle cell anemia; Monthly erythrocyte transfusions TREATS anemia IN Sickle cell anemia; Surveillance echocardiograms MONITOR diastolic dysfunction IN Sickle cell anemia; Hydroxyurea administration INCREASES worsening in diastolic parameters IN Sickle cell anemia; Hydroxyurea administration DECREASES fetal hemoglobin (HbF) levels IN Sickle cell anemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Hydroxyurea administration DECREASES fetal hemoglobin (HbF) levels IN Sickle cell anemia

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - Disease-modifying therapy
    - Surveillance echocardiograms
    - Hydroxyurea administration
    - Monthly erythrocyte transfusions
  symptoms:
    - Diastolic dysfunction
    - Increase in left atrial volume index (LAVi)
    - HP:0001903
    - High baseline E/e'
    - LV dilation
    - Worsening in diastolic parameters
    - Decrease in septal e'
    - Decrease in fetal hemoglobin (HbF) levels
  chemicals:
    - CHEBI:44423
  action_annotation_relationships:
    - subject: Disease-modifying therapy
      predicate: TREATS
      object: diastolic dysfunction
      qualifier: MONDO:0011382
      subject_qualifier: with hydroxyurea
      subject_extension: CHEBI:44423
    - subject: Disease-modifying therapy
      predicate: TREATS
      object: increase in left atrial volume index (LAVi)
      qualifier: MONDO:0011382
      subject_qualifier: with hydroxyurea
      subject_extension: CHEBI:44423
    - subject: Disease-modifying therapy
      predicate: PREVENTS
      object: HP:0001903
      qualifier: MONDO:0011382
      subject_qualifier: with hydroxyurea
      subject_extension: CHEBI:44423
    - subject: <erythrocyte transfusions>
      predicate: <TREATS>
      object: <anemia>
      qualifier: <Sickle cell anemia>
      subject_qualifier: <Monthly>
      subject_extension: <erythrocyte>
    - subject: Surveillance echocardiograms
      predicate: MONITOR
      object: diastolic dysfunction
      qualifier: MONDO:0011382
    - subject: administration
      predicate: INCREASES
      object: worsening in diastolic parameters
      qualifier: MONDO:0011382
      subject_extension: CHEBI:44423
    - subject: administration
      predicate: DECREASES
      object: fetal hemoglobin (HbF) levels
      qualifier: MONDO:0011382
      subject_extension: CHEBI:44423
named_entities:
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: CHEBI:35480
    label: analgesics
  - id: HP:0001944
    label: dehydration
  - id: HP:0001903
    label: anemia
  - id: MAXO:0000756
    label: Transfusion
  - id: HP:0001396
    label: Cholestasis
  - id: HP:0001297
    label: Stroke
  - id: HP:0000083
    label: Kidney failure
  - id: CHEBI:50858
    label: Corticosteroids
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0007760
    label: Sickle cell disease (SCD)
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplant (HSCT)
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:9570
    label: Thiotepa
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimen
  - id: HP:0012532
    label: chronic pain
  - id: MONDO:0020121
    label: Muscular dystrophy
  - id: MONDO:0004992
    label: Cancer
  - id: MONDO:0005015
    label: Diabetes
  - id: MONDO:0011382
    label: Sickle cell disease
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0001017
    label: vaccination
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: CHEBI:28876
    label: Melphalan
  - id: MONDO:0005570
    label: hematological disorders
  - id: MONDO:0011549
    label: Hyperhemolytic syndrome (HHS)
  - id: MAXO:0001077
    label: Splenectomy
  - id: HP:0001896
    label: Reticulocytopenia
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:64357
    label: Rituximab
  - id: HP:0000789
    label: infertility
  - id: CHEBI:22333
    label: alkylating agents
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MONDO:0005453
    label: congenital heart disease
  - id: MONDO:0018585
    label: Pediatric Arterial Ischemic Stroke
  - id: CHEBI:119915
    label: Fentanyl
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0001945
    label: Fever
  - id: HP:0200023
    label: Priapism
  - id: HP:0004395
    label: malnutrition
  - id: MONDO:0005136
    label: Malaria
  - id: CHEBI:8455
    label: Proguanil
  - id: HP:0007902
    label: Vitreous haemorrhage
  - id: HP:0011958
    label: Retinal tear
  - id: HP:0000541
    label: Retinal detachment
  - id: HP:0011506
    label: Choroidal neovascularization
  - id: HP:0000572
    label: Visual loss
  - id: HP:0001139
    label: abnormal/conditional transcranial doppler (TCD)
  - id: MAXO:0000503
    label: mechanical ventilation
  - id: HP:0002878
    label: respiratory failure
  - id: HP:0000988
    label: skin rash
  - id: HP:0001873
    label: thrombocytopenia
  - id: MONDO:0020380
    label: Sickle cell anaemia (SCA)
  - id: HP:0012531
    label: Pain
  - id: CHEBI:32250
    label: Tramadol hydrochloride
  - id: CHEBI:6129
    label: Ketorolac
  - id: CHEBI:47381
    label: Diclofenac
  - id: MAXO:0000946
    label: neurosurgery
  - id: MONDO:0005300
    label: Chronic kidney disease
  - id: HP:0100806
    label: Sepsis
  - id: HP:0002204
    label: Pulmonary embolism
  - id: HP:0012622
    label: Chronic kidney disease
  - id: HP:0001649
    label: increased heart rate
  - id: MAXO:0000573
    label: Assisted reproductive technologies (ART)
  - id: HP:0001394
    label: cirrhosis
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:4356
    label: deferoxamine
  - id: CHEBI:49005
    label: deferasirox
  - id: HP:0012378
    label: Fatigue
  - id: MONDO:0013730
    label: Graft-versus-host disease (GVHD)
  - id: HP:0004870
    label: Chronic hemolytic anemia
  - id: HP:0100724
    label: Hypercoagulability
  - id: HP:0004936
    label: Venous thromboembolism
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: HP:0100749
    label: Chest pain
  - id: HP:0030830
    label: Crackles
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:74213
    label: ribonucleotide reductase inhibitors
  - id: MAXO:0000087
    label: Massage
  - id: MONDO:0002280
    label: Anemia
  - id: HP:0001915
    label: Aplastic anemia
  - id: CHEBI:9908
    label: Ursolic acid
  - id: CHEBI:16243
    label: Quercetin
  - id: CHEBI:28775
    label: Hesperidin
  - id: HP:0000739
    label: Anxiety
  - id: MAXO:0001298
    label: therapy
  - id: HP:0002863
    label: Leukemia/Myelodysplastic syndrome (MDS)
  - id: HP:0002664
    label: Cancer
  - id: HP:0004430
    label: severe combined immunodeficiency (SCID)
  - id: HP:0003560
    label: muscular dystrophy
  - id: HP:0100615
    label: ovarian cancer
  - id: HP:0002861
    label: melanoma
  - id: CHEBI:5790
    label: Hydromorphone
  - id: CHEBI:17303
    label: Morphine
  - id: HP:0004804
    label: Congenital hemolytic anemia
  - id: MAXO:0000010
    label: Cognitive behavioural therapy (CBT)
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0012418
    label: hypoxia
  - id: HP:0020071
    label: Viremia
  - id: MAXO:0000831
    label: peripheral blood smear
  - id: MAXO:0000588
    label: nucleic acid testing
  - id: HP:0030833
    label: neck pain
  - id: HP:0000613
    label: photophobia
  - id: HP:0025143
    label: chills
  - id: HP:0002315
    label: headache
  - id: HP:0004396
    label: loss of appetite
  - id: MONDO:0800385
    label: Iron overload
  - id: MAXO:0000376
    label: Liver biopsy
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0001479
    label: Allogeneic Hematopoietic Stem Cell Transplantation
  - id: HP:0100601
    label: Eclampsia
  - id: HP:0033677
    label: Acute respiratory distress syndrome
